# Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

> **NCT06896110** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Andrew P. Groves** · enrollment: 34 (estimated)

## Conditions studied

- Glioblastoma (GBM)
- Diffuse Midline Glioma (DMG)
- Astrocytoma, IDH-Mutant, Grade 4
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Gliosarcoma of Brain

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Azacitidine (AZA)
- **PROCEDURE:** lumbar puncture
- **DIAGNOSTIC_TEST:** MRI Contrast

## Key facts

- **NCT ID:** NCT06896110
- **Lead sponsor:** Andrew P. Groves
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-06-05
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06896110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06896110, "Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06896110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*